Average Co-Inventor Count = 3.16
ph-index = 2
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. The University of Texas System (9 from 5,450 patents)
2. The United States of America, As Represented by the Secretary, Department of Health and Human Services (3 from 3,539 patents)
3. The University of British Columbia (3 from 932 patents)
4. University of California (2 from 15,475 patents)
5. University of Colorado (1 from 1,381 patents)
6. Texas Southern University (1 from 6 patents)
9 patents:
1. 12351560 - Next generation FKBP52 targeting drugs for the treatment of prostate and breast cancer
2. 11878961 - Next generation FKBP52 targeting drugs for the treatment of prostate and breast cancer
3. 10682339 - Pharmaceutical compositions directly targeting FKBP52 for the treatment of prostate cancer and methods of using same
4. 10434075 - FKBP52 specific androgen receptor inhibitor, MJC13, for use in treating breast cancer
5. 10322113 - Pharmaceutical compositions directly targeting FKBP52 for the treatment of prostate cancer and methods of using same
6. 10010534 - Intravenous formulation and LC/MS/MS analysis method for GMC1
7. 9782399 - Pharmaceutical compositions which inhibit FKBP52-mediated regulation of androgen receptor function and methods of using same
8. 9233973 - Pharmaceutical compositions which inhibit FKBP52-mediated regulation of androgen receptor function and methods of using same
9. 8859207 - Pharmaceutical compositions which inhibit FKBP52-mediated regulation of androgen receptor function and methods of using same